A Phase 1 interventional study of DC-806 and Itraconazole in Healthy Volunteers, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study was to assess the effect of a cytochrome P450 3A4 (CYP3A4) inhibitor (itraconazole) and CYP3A4 inducer (carbamazepine) on the single dose pharmacokinetics (PK) of DC-806 coadministered with itraconazole or carbamazepine in healthy male and female participants.
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.
First submitted the day DICE Therapeutics, Inc. became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any other condition or prior therapy that, in the Investigator's opinion, would confound or interfere with the evaluation of safety, tolerability, or pharmacokinetics (PK) of the study drug, interfere with study compliance, or preclude .
Cohort 2 Only:
Presence of active suicidal ideation or positive suicide behavior using the "Baseline/Screening" version of the C-SSRS and with either of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received: Period 1: A single oral dose of 200 milligram (mg) DC-806 under fasted conditions on Day 1. Period 2: Multiple oral doses of 200 mg itraconazole once daily (QD) under fed conditions on Days 4 to 6. Period 3: Day 7: A single oral dose of 200 mg DC-806 was administered 2 hours after a single oral dose of 200 mg itraconazole under fasted conditions, in the morning on Day 7. Day 8 to Day 10: QD dosing of itraconazole 200 mg was continued until Day 10 under fed conditions.
Drug: DC-806 · Drug: Itraconazole
Participants received: Period 1: A single oral dose of 800 mg DC-806 on Day 1 under fasted conditions. Period 2: Multiple ascending oral doses of twice daily (BID) carbamazepine, under fed conditions, as follows: Day 4 to Day 5: BID doses of 100 mg carbamazepine. Day 6 to Day 7: BID doses of 200 mg carbamazepine. Day 8 to Day 17: BID doses of 300 mg carbamazepine. Period 3: Day 18, morning dosing: a single oral dose of 800 mg DC-806 was coadministered with 300 mg carbamazepine under fasted conditions. Day 18, Evening dosing: a single oral dose of 300 mg carbamazepine were administered under fed conditions. Day 19 to Day 20: BID administration of 300 mg carbamazepine was continued until Day 20, under fed conditions. Day 21 to Day 22: BID doses of 200 mg carbamazepine, under fed conditions. Day 23 to Day 24: BID doses of 100 mg carbamazepine, under fed conditions.
Drug: DC-806 · Drug: Carbamazepine
Oral tablets
Also known as: LY4100504
Oral capsules
Oral tablets
Cohort 1: Maximum Observed Plasma Concentration (Cmax) of DC-806
Cmax of DC-806 alone on Day 1 and when coadministered with itraconazole on Day 7.
Time frame: Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
Cohort 1: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of DC-806
AUC0-t of DC-806 alone on Day 1 and when coadministered with itraconazole on Day 7.
Time frame: Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
Cohort 1: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of DC-806
AUC0-inf of DC-806 alone on Day 1 and when coadministered with itraconazole on Day 7.
Time frame: Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 7 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
Cohort 2: Maximum Observed Plasma Concentration (Cmax) of DC-806
Cmax of DC-806 alone on Day 1 and when coadministered with carbamazepine on Day 18.
Time frame: Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
Cohort 2: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of DC-806
AUC0-t of DC-806 alone on Day 1 and when coadministered with carbamazepine on Day 18.
Time frame: Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
Cohort 2: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of DC-806
AUC0-inf of DC-806 alone on Day 1 and when coadministered with carbamazepine on Day 18.
Time frame: Day 1 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72 hours postdose), Day 18 (Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96 hours postdose)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug.
Time frame: Cohort 1: Day 1 up to Day 23; Cohort 2: Day 1 up to Day 33.
Participants were enrolled into two cohorts, with each cohort having 3 treatment periods. * Cohort 1: Period 1 (Days 1 to 3), Period 2 (Days 4 to 6), Period 3 (Days 7 to 10). * Cohort 2: Period 1 (Days 1 to 3), Period 2 (Days 4 to 17), Period 3 (Days 18 to 25).
| Milestone | Cohort 1 (DC-806 200 mg / Itraconazole) | Cohort 2 (DC-806 800 mg / Carbamazepine) |
|---|---|---|
| Started | 17 | 16 |
| Safety analyses set | 17 | 16 |
| Completed | 15 | 14 |
| Not completed | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Adverse event | 0 | 2 |
Cmax of DC-806 alone on Day 1 and when coadministered with itraconazole on Day 7.
| nanograms per milliliter (ng/mL) | Cohort 1 (DC-806 200 mg / Itraconazole) |
|---|---|
| Day 1 | 383 ± 53.6 |
| Day 7 | 1490 ± 46.3 |
AUC0-t of DC-806 alone on Day 1 and when coadministered with itraconazole on Day 7.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 1 (DC-806 200 mg / Itraconazole) |
|---|---|
| Day 1 | 983 ± 49.6 |
| Day 7 | 6640 ± 48.6 |
AUC0-inf of DC-806 alone on Day 1 and when coadministered with itraconazole on Day 7.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 1 (DC-806 200 mg / Itraconazole) |
|---|---|
| Day 1 | 1000 ± 48.9 |
| Day 7 | 6970 ± 46.5 |
Cmax of DC-806 alone on Day 1 and when coadministered with carbamazepine on Day 18.
| nanograms per milliliter (ng/mL) | Cohort 2 (DC-806 800 mg / Carbamazepine) |
|---|---|
| Day 1 | 2740 ± 40.5 |
| Day 18 | 1100 ± 34.6 |
AUC0-t of DC-806 alone on Day 1 and when coadministered with carbamazepine on Day 18.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 2 (DC-806 800 mg / Carbamazepine) |
|---|---|
| Day 1 | 7720 ± 31.0 |
| Day 18 | 2850 ± 21.8 |
AUC0-inf of DC-806 alone on Day 1 and when coadministered with carbamazepine on Day 18.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 2 (DC-806 800 mg / Carbamazepine) |
|---|---|
| Day 1 | 8000 ± 29.5 |
| Day 18 | 2870 ± 21.7 |
A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug.
| Participants | Cohort 1: DC-806 200 mg (Days 1 to 3) | Cohort 1: Itraconazole (Days 4 to 6) | Cohort 1: DC-806 200 mg + Itraconazole (From Day 7) | Cohort 1: Overall (DC-806 200 mg / Itraconazole) | Cohort 2: DC-806 800 mg (Days 1 to 3) | Cohort 2: Carbamazepine (Days 4 to 17) | Cohort 2: DC-806 800 mg + Carbamazepine (From Day 18) | Cohort 2: Overall (DC-806 800 mg / Carbamazepine) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 1 | 0 | 0 | 1 | 2 | 8 | 2 | 10 |
Collected over Cohort 1: Day 1 up to Day 23; Cohort 2: Day 1 up to Day 33.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: DC-806 200 mg (Days 1 to 3) | 0/17 (0%) | 0/17 (0%) | 1/17 (5.9%) |
| Cohort 1: Itraconazole (Days 4 to 6) | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Cohort 1: DC-806 200 mg + Itraconazole (From Day 7) | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Cohort 1: Overall (DC-806 200 mg / Itraconazole) | 0/17 (0%) | 0/17 (0%) | 1/17 (5.9%) |
| Cohort 2: DC-806 800 mg (Days 1 to 3) | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| Cohort 2: Carbamazepine (Days 4 to 17) | 0/16 (0%) | 0/16 (0%) | 8/16 (50%) |
| Cohort 2: DC-806 800 mg + Carbamazepine (From Day 18) | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| Cohort 2: Overall (DC-806 800 mg / Carbamazepine) | 0/16 (0%) | 0/16 (0%) | 10/16 (62.5%) |
| Event | Cohort 1: DC-806 200 mg (Days 1 to 3) | Cohort 1: Itraconazole (Days 4 to 6) | Cohort 1: DC-806 200 mg + Itraconazole (From Day 7) | Cohort 1: Overall (DC-806 200 mg / Itraconazole) | Cohort 2: DC-806 800 mg (Days 1 to 3) | Cohort 2: Carbamazepine (Days 4 to 17) | Cohort 2: DC-806 800 mg + Carbamazepine (From Day 18) | Cohort 2: Overall (DC-806 800 mg / Carbamazepine) |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/17 | 0/16 | 0/16 | 0/17 | 1/16 | 4/16 | 1/14 | 6/16 |
| DizzinessNervous system disorders | 0/17 | 0/16 | 0/16 | 0/17 | 0/16 | 3/16 | 0/14 | 3/16 |
| ConstipationGastrointestinal disorders | 0/17 | 0/16 | 0/16 | 0/17 | 0/16 | 2/16 | 0/14 | 2/16 |
| EructationGastrointestinal disorders | 0/17 | 0/16 | 0/16 | 0/17 | 0/16 | 0/16 | 1/14 | 1/16 |
| DysgeusiaNervous system disorders | 0/17 | 0/16 | 0/16 | 0/17 | 0/16 | 0/16 | 1/14 | 1/16 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/17 | 0/16 | 0/16 | 0/17 | 0/16 | 1/16 | 0/14 | 1/16 |
| Ear discomfortEar and labyrinth disorders | 0/17 | 0/16 | 0/16 | 0/17 | 0/16 | 1/16 | 0/14 | 1/16 |
| HypoacusisEar and labyrinth disorders | 0/17 | 0/16 | 0/16 | 0/17 | 0/16 | 1/16 | 0/14 | 1/16 |
| DyspepsiaGastrointestinal disorders | 0/17 | 0/16 | 0/16 | 0/17 | 0/16 | 1/16 | 0/14 | 1/16 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/17 | 0/16 | 0/16 | 0/17 | 0/16 | 1/16 | 0/14 | 1/16 |
All enrolled participants.
| Age, Continuous(years) | Cohort 1 (DC-806 200 mg / Itraconazole) | Cohort 2 (DC-806 800 mg / Carbamazepine) | Total |
|---|---|---|---|
| Mean | 28.2 ± 8.55 | 37.4 ± 11.41 | 32.7 ± 10.94 |
| Sex: Female, Male(Participants) | Cohort 1 (DC-806 200 mg / Itraconazole) | Cohort 2 (DC-806 800 mg / Carbamazepine) | Total |
|---|---|---|---|
| Female | 0 | 2 | 2 |
| Male | 17 | 14 | 31 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 (DC-806 200 mg / Itraconazole) | Cohort 2 (DC-806 800 mg / Carbamazepine) | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 6 | 9 |
| Not Hispanic or Latino | 13 | 9 | 22 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Cohort 1 (DC-806 200 mg / Itraconazole) | Cohort 2 (DC-806 800 mg / Carbamazepine) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 3 | 2 | 5 |
| White | 11 | 12 | 23 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2023 to primary completion in Sep 2023, 1 month.
Results were first posted in Oct 2026, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: DC-806
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company →